MedTrace Logo

DETERMINE: Detemir vs NPH

NCT05124457 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2023-09-26

No results posted yet for this study

Summary

The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.

Conditions

  • Gestational Diabetes
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Detemir

Patients are to receive insulin detemir

DRUG

Insulin NPH

Patients are to receive insulin NPH

Sponsors & Collaborators

Principal Investigators

  • Christina Han, MD · University of California, Los Angeles

  • Michael Richley, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2025-06-30
Completion
2025-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05124457 on ClinicalTrials.gov